17 results
424B3
SRZN
Surrozen Inc
7 Apr 23
Prospectus supplement
5:20pm
to activate the Wnt pathway in injured tissue where certain Fzd receptors are expressed and the natural Wnt ligand is disturbed.
Key characteristics of our … antibodies both in naïve and injured intestinal tissue and in DSS models.
Figure 12. Fzd5 is highly expressed in intestinal tissue from a DSS mouse
POS AM
SRZN
Surrozen Inc
31 Mar 23
Prospectus update (post-effective amendment)
9:09am
candidates, SZN-1326 and SZN-413, utilize our SWAP technology and are designed to activate the Wnt pathway in injured tissue where certain Fzd receptors … to that seen in IBD
patients. We identified SZN-1326 through testing of multiple SWAP antibodies both in naïve and injured intestinal tissue and in DSS
8-K
EX-99.1
SRZN
Surrozen Inc
15 Nov 22
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:12pm
Gastroenterology in 2022, findings demonstrating that SZN-1326 showed the most rapid and robust repair of the injured colon epithelium of evaluated
424B3
f3jd5gz
5 Apr 22
Prospectus supplement
4:43pm
424B3
87fir24w kg4kuvi
30 Mar 22
Prospectus supplement
9:13pm
POS AM
49bext5si1ev9d8iv
28 Mar 22
Prospectus update (post-effective amendment)
9:34pm
424B3
o21u1ct
10 Nov 21
Prospectus supplement
12:00am
8-K
EX-99.4
4glhxff3cmohl5mh
15 Apr 21
Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration
8:42am
425
EX-99.4
u6aykbbnu ya
15 Apr 21
Business combination disclosure
8:40am
8-K
EX-10.5
j35x4tbi8zhix277i6w
25 Nov 20
Consonance-HFW Acquisition Corp. Announces Pricing of Its Initial Public Offering
9:07am
- Prev
- 1
- Next